BASF gets a higher fine over animal-feed cartel: court upholds levy against Akzo Nobel, reduces UCB penalty
Article Abstract:
The European Union's Court of First Instance raised the fine levied by the European Commission on German firm BASF AG for its role in an animal-feed cartel. The fine increased from 34.97 mil euro to 35.02 mil euro. The court also upheld the 20.99 mil euro cartel fine for Dutch firm Akzo Nobel N.V., but lowered the fine imposed on Belgian firm UCB SA from 10.38 mil to 1.87 mil euro.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
EU Threatens 2 Member States With Beef Ban
Article Abstract:
Beef exports from Germany and Netherlands may be banned by the European Commission. The proposed beef ban, which is related to food safety violations by the two member states, is part of the EU's effort to control the spread of mad-cow disease.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
For the Greeks, the euro was a taxing matter
Article Abstract:
The tax collection system has become more stringent in Greece during the 1990s,and, as a result, the economic situation is better in the country. Greece will join the euro on Jan 1, 2001.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Students Help Govern HYY. After 25 years, shareholder lawsuit against Loblaw rages on in Canada
- Abstracts: Antihistamines. Medicated cleansers and acne remedies. Consumer products: overview
- Abstracts: War clouds over Pakistan. APEC backs U.S. in war, but disagrees with tactics. Bush should be less romantic about one Korea...
- Abstracts: Drug firms agree to settle U.S. suit for $176 million. U.S. jury deadlocks on Genentech case. Drug Makers' Fight For Patent Rights Puts Them in a Vise